As an estimated 30,000 cancer specialists prepare to converge on the city of Chicago in a couple of weeks for the so-called "Super Bowl of Cancer" - or, as analysts at Wedbush PacGrow Life Sciences put it, "the most important and most unmanageable" of the annual biotech meetings - investors already have been placing their bets on companies expected to wow attendees at this year's American Society of Clinical Oncology meeting. (BioWorld Today)
Jazz Pharmaceuticals Inc. is raising about $58.5 million in a public offering to pay off a sizeable chunk of its outstanding debt ahead of an FDA decision on fibromyalgia drug JZP-6 (sodium oxybate), expected this fall. (BioWorld Today)
CHICAGO - Before the so-called genomics bubble burst, it seemed any company with the word "genomics" in its name was a sure winner with investors, and the "average" biotech was able to stay afloat in both public and private markets. (BioWorld Today - 2010 BIO)
